breast cancer

The company discussed expectations for how its products will fare against rivals into next year based on recent data and coverage decisions, and on expected reimbursement changes.

Broad Institute and Dana-Farber Cancer Institute researchers have released the first annotated genomic data as part of a public data sharing effort in this disease. 

CEO Anders Rylander said the company will initially market its DiviTum assay for breast cancer cases, though it could be used to monitor cell proliferation in all cancer types.

Test volume was up 5 percent, but the company's total revenue of $83.8 million was negatively affected by hurricanes in the US, company executives said.

The company believes the approach could allow researchers to profile tumor signaling pathways via blood or urine samples, similar to how ctDNA analysis is used.

Expression and copy number profiles from histologically normal duct tissue near tumors suggest a "field of cancerization" may exist in epithelial cells around cancer.

This Week in PNAS

In PNAS this week: genes selected for in potato domestication, method sequencing and haplotyping analysis on single cells, and more.

This Week in Nature

In Nature this week: new class of base editors, additional breast cancer risk loci, and more.

Using genome-wide association and targeted sequencing approaches, research teams continue to tally up genetic contributors and candidate genes in breast cancer.

The agency has granted the drug and CDx priority review, which Myriad expects to conclude during its fiscal third-quarter ending March 31, 2018.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.